Centella triterpenes, primarily derived from the plant Centella asiatica (also known as gotu kola), have been investigated for their potential benefits in treating eczema (atopic dermatitis). The active components, including asiaticoside, madecassoside, and asiatic acid, are known for their anti-inflammatory and wound-healing properties. Scientific studies have shown that these triterpenes can modulate inflammation, enhance collagen synthesis, and support skin barrier repair, which are relevant mechanisms in the management of eczema.

Several preclinical studies (in vitro and animal models) have demonstrated that Centella triterpenes reduce inflammatory cytokine production and improve skin healing. A few small human studies and clinical trials have indicated some benefit in reducing symptoms of skin irritation and improving skin barrier function, though direct high-quality clinical evidence specific to eczema is limited. Most clinical research has focused on wound healing and general dermatitis rather than eczema specifically.

Therefore, while there is some scientific rationale and preliminary evidence for using Centella triterpenes in eczema due to their anti-inflammatory and skin-repairing effects, robust clinical trials are lacking. The current evidence base is rated as modest (2 out of 5), indicating a need for more targeted, high-quality research to confirm efficacy for eczema treatment.